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Objectives. We sought to broaden assessment of the economic
impact of percutaneous transluminal coronary angioplasty
(PTCA) revascularization salvage strategies by taking into ac-
count costs, revenues, the off-setting effects of prevented clinical
complications and the effects of payer mix.
Background. Previous economic analyses of PTCA have focused
on the direct costs of treatment but have not accounted either for
associated revenues or for the ability of costly salvage techniques
such as coronary stenting to reduce even costlier complications.
Methods. Procedural costs, revenues and contribution margins
(i.e., “profit”) were measured for 765 consecutive PTCA cases to
assess the economic impact of salvage techniques (prolonged
heparin administration, thrombolysis, intracoronary stenting or
use of perfusion balloon catheters) and clinical complications
(myocardial infarction, coronary artery bypass graft surgery
[CABG] or acute vessel closure with repeat PTCA). To assess the
economic impact of various salvage techniques for failed PTCA,
we used actual 1995 financial data as well as models of various
mixes of fee-for-service, diagnosis-related group (DRG) and capi-
tated payers.
Results. Under fee-for-service arrangements, most salvage tech-
niques were profitable for the hospital. Stents were profitable at
almost any level of clinical effectiveness. Under DRG-based sys-
tems, most salvage techniques such as stenting produced a
financial loss to the hospital because one complication (CABG)
remained profitable. Under capitated arrangements, stenting and
other salvage modalities were profitable only if they were clinically
effective in preventing complications in >50% of cases in which
they were used.
Conclusions. The economic impact of PTCA salvage techniques
depends on their clinical effectiveness, costs and revenues. In
reimbursement systems dominated by DRG payers, salvage tech-
niques are not rewarded, whereas complications are. Under
capitated systems, the level of clinical effectiveness needed to
achieve cost savings is probably not achievable in current practice.
Further studies are needed to define equitable reimbursement
schedules that will promote clinically effective practice.
(J Am Coll Cardiol 1997;30:894–900)
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The delivery of interventional cardiology services is expensive,
involving both considerable fixed costs (cardiac catheterization
laboratories and inpatient hospital facilities) and large variable
costs (disposable equipment and concentrated personnel
time). Because of the high prevalence of coronary disease and
the expenses involved in providing the service, interventional
cardiology has appropriately become the subject of consider-
able scrutiny (1–3). Previous studies in this area (1,2,4–8) have
focused exclusively on the single dimension of accounting for
costs associated with percutaneous transluminal coronary an-
gioplasty (PTCA). A recent American College of Cardiology
consensus document (9) emphasized that previous economic
analyses did not account for the cost-savings potential of
stenting in preventing emergency coronary artery bypass graft
surgery (CABG).
Complications of PTCA such as myocardial infarction,
CABG or repeat PTCA (10–14) add considerably to the costs
of an interventional program (15). Various salvage techniques,
including either technical tools (intracoronary stenting [16,17]
or perfusion balloon catheters [18,19]) or pharmacologic strat-
egies (prolonged postprocedure heparin administration [20] or
the intracoronary administration of thrombolytic agents
[21,22]) have been applied in an effort to treat or prevent vessel
closure. Our aim was to expand the economic analysis by
incorporating the additional dimensions of the clinical context
within which PTCA is performed; the need to account for costs
of multiple simultaneous salvage therapies, associated reve-
nues, savings achieved from prevented complications and the
payer mix. Previous economic analyses of PTCA (1–3,8,16)
have included few or none of these other dimensions. Health
care economic research must specify the perspective it adopts
and must maintain this perspective consistently (23). All
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previous studies (1,2,4–8,15) have implicitly adopted the per-
spective of the hospital by assessing hospital costs. We adopt
the same perspective explicitly. This perspective is relevant to
physicians because it is the economic platform on which the
medical profession functions. Physicians are both responsible
for and dependent on the economic well-being of the hospitals
in which they work.
Methods
Of 817 consecutive interventional cases during a 13-month
period (February 1994 to February 1995), 765 were included in
our study. To achieve comparability of data across clinical
strata and among salvage modalities, we focused on cases of
conventional PTCA. Patients with separate planned PTCAs in
different coronary arteries on different days (“staged PTCAs,”
n 5 22) were excluded because there was no satisfactory
method of assigning inpatient hospital costs to each of the two
or more PTCA procedures. Primary directional coronary
atherectomies (n 5 26) were excluded. There were no primary
stent implantations during the study. Four patients (none of
whom had received a stent or thrombolysis or had sustained
any complication) were excluded because their hospital charts
could not be located.
Complications included CABG (n 5 16), myocardial infarc-
tion (n 5 15) and sudden out-of-laboratory vessel closure
involving successful repeat PTCA (n 5 17). We tracked all
in-hospital complications of PTCA cases, whether they oc-
curred in the catheterization laboratory or later in the hospital
stay. The salvage modalities considered included “bail-out”
intracoronary stent implantation (n 5 12), prolonged inflation
with a perfusion balloon catheter (n 5 14), intracoronary
administration of thrombolytic agents (n 5 15) and prolonged
postprocedure heparin administration (n 5 184). The latter
was defined as heparin administration continued beyond the
1st 24 h after PTCA, which was the standard of care in our
institution. Angiographic success was defined as achieving a
final stenosis of ,50% in at least one lesion with attempted
PTCA. Clinical success was defined as angiographic success in
the absence of any complications.
Revenue data were obtained from our patient billing de-
partment and were complete for all patients. Our mature cost
accounting system systematically and comprehensively cap-
tures fixed and variable costs by using accepted accounting
methods. Each patient care activity has assigned to it a cost
that has been derived by summing all identified variable costs
as well as an allocated component of fixed costs. The allocation
of institutional overhead to cost centers is based on activity-
based costing. Subsequent cost center overhead and fixed costs
are assigned to specific patient care activities by a collaborative
process involving the cost center manager and the cost-
accounting staff. The cost accountants ensure that all costs are
allocated comprehensively and in accordance with standard
cost-accounting methods, whereas the managers assess that
costs assigned to specific patient care activities represent a fair
and equitable allocation. Cost information is linked to each
patient charge code. An individual patient’s cost summary is
thus derived from his or her itemized hospital bill.
The contribution margin for each case was calculated as
revenues minus costs. However, the relevant figure in cases of
complications and salvage treatments is not the total costs or
the entire contribution margin but the increment (or decre-
ment) above or below that which would have occurred had the
case proceeded in an uncomplicated fashion.
Patients may undergo more than one salvage modality and
costs in these cases have to be allocated to each modality. We
first analyzed our data set using stepwise regression analysis
with costs as the dependent variable and each of the clinical
indications, complications and salvage techniques as an inde-
pendent variable. An F value of 3.96 was accepted as evidence
of a significant relation.
Standard statistical techniques are insufficient to correctly
identify the incremental costs of complications and salvage
techniques. Stepwise logistic regression will identify a statisti-
cally significant relation only if the independent variable
accounts for a significant amount of the residual variation in
the dependent variable in the entire cohort. Interventions that
are used relatively infrequently are thus unlikely to appear as
statistically significant independent variables. However, it
would be incorrect to conclude that there is no incremental
cost associated with their use. We thus sought to identify the
incremental costs and contribution margin through iterative
analysis, a method frequently employed in business to solve
problems that can be expressed in terms of two or more
equations whose results refer back to one another in a circular
fashion (24). The incremental cost of a given salvage technique
was calculated as the average cost of cases in which that
technique is used minus the costs attributable to uncompli-
cated PTCA and costs attributable to any concomitantly used
salvage technique. Therefore, the formula for each salvage
modality necessarily refers to the formulas for every other
modality. The incremental cost can be computed by multiple
reiterations of the formulas. We programmed the calculation
to proceed through a maximum of 10,000 iterations or until the
change between iterations was less than 1 cent. The formulas
used are detailed in the Appendix.
To account for differences in case mix, PTCAs were strat-
ified according to indication, and all analyses were carried out
within a given clinical stratum. Patients underwent PTCA for
stable angina, unstable angina, postmyocardial infarction, as
primary therapy for acute myocardial infarction, cardiogenic
shock and “other” indications. Once the incremental costs and
contribution margin for each complication and salvage tech-
nique were calculated within the clinical strata, they were
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
DRG 5 diagnosis-related group
PTCA 5 percutaneous transluminal coronary angioplasty
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combined by summing them, weighted for the relative fre-
quency of each clinical indication. We eliminated from analysis
the few cases of cardiogenic shock and the PTCAs performed
for “other” indications. Only one patient with cardiogenic
shock underwent PTCA without complication and without
salvage technique, an insufficient basis for determining the
costs of uncomplicated, “unsalvaged” PTCA in this clinical
stratum. To include patients with cardiogenic shock with those
in the group with myocardial infarction would introduce an
unfair bias against salvage techniques as the patients with
shock invariably had very high costs that could not be con-
strued as due to the salvage techniques. Similarly, we excluded
the “other” indication cases because these patients were an
extremely heterogeneous group with no clinically meaningful
unifying theme. Most of the costs of these patient’s hospital
stays were due to treatment of other dimensions of their
cardiac disease, such as arrhythmias requiring electrophysi-
ologic evaluations.
To model a purely fee-for-service world, we assigned to
each case a reimbursement of a percent of actual charges. The
percent used in this calculation was the average percent our
institution actually received in cases covered by fee-for-service
payers in 1995. To model a diagnosis-related group (DRG)
payer environment, we assigned to each case reimbursement
based on an average of the two largest DRG payers in our
current mix (one being Medicare). Finally, to model a capi-
tated environment, we assumed no revenue associated with any
episode of care. We modeled a truly capitated arrangement
with a fixed, absolute revenue to the provider organization
based on the number of covered lives and not on alternative
arrangements such as discounted, fixed payments for each
percutaneous intervention. These alternative arrangements,
although fairly common for managed care payers and provid-
ers, are merely variations on the DRG theme and do not
represent true capitation.
Central to our analysis is the concept that salvage tech-
niques are not adequately described by their direct costs and
revenues alone. A successful salvage technique will prevent
complications and their attendant costs. To model this, we can
assume any level of clinical effectiveness. If a salvage modality
is 0% effective in preventing complications, it will have no cost
offset. A technique that is 100% effective (e.g., if each stent
implanted for threatened vessel closure prevents one case of
CABG) will have its costs offset by saving the costs of a
complication.
Finally, we varied the degree to which the different types of
payers had penetrated the market. Although it is possible for
us to calculate the contribution margins of a salvage technique
by using any proportion of different payers, for clarity and
simplicity we restrict our reported results to varying the market
mix between two pairs of payers, paralleling the historical
developments in the marketplace. We first moved the market
from a 100% fee-for-service/0% DRG-based to a 0% fee-for-
service/100% DRG-based distribution. The second frontier we
modeled was from a 100% DRG-based/0% capitated to a 0%
DRG-based/100% capitated environment. We generated a
family of curves to demonstrate the combined effects of payer
mix and clinical efficacy on cost effectiveness.
Results
The costs per case stratified by clinical indication are
presented in Figure 1. PTCA was performed in 206 patients for
stable angina, in 337 for unstable angina, in 182 after myocar-
dial infarction, in 25 as primary therapy for myocardial infarc-
tion, in 4 for cardiogenic shock and in 11 for other indications.
Our payer mix is summarized in Table 1. Angiographic success
was achieved in 668 cases (87.3%) and clinical success in 638
cases (83.4%).
Stepwise regression analysis revealed a significant relation
between cost and the following independent variables (figures
in parentheses are the regression coefficients): indications—
stable angina (22,783), cardiogenic shock (19,452), “other
indication” (8,856); complications—CABG (27,412), myocar-
dial infarction (6,253), repeat PTCA for out-of-laboratory
Figure 1. Total costs for patients undergoing PTCA in each of six
clinical settings. MI 5 myocardial infarction.
Table 1. University of Vermont Payer Mix, 1995
Source Market Share (%)
Blue Cross/Blue Shield 23.0
Commercial 11.8
Health maintenance organizations 10.8
Medicare 42.1
Medicaid 6.4
None 5.9
Type of reimbursement
Fee for service 11.8
Discounted fee for service 33.7
Diagnosis-related group 48.6
None 5.9
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closure (9,698); salvage techniques—prolonged heparin admin-
istration (1,544), stents (6,023), thrombolysis (3,693). The
regression coefficients represent the dollar amount difference
between a PTCA case including the independent variable and
the “average” PTCA case.
The total costs of uncomplicated PTCA cases, complicated
cases and cases involving salvage techniques are shown in
Table 2. Table 2 also lists the incremental cost of each
complication and salvage technique and the incremental con-
tribution margin of complications and salvage techniques
under four payer environments: the 1995 University of Ver-
mont payer mix, purely fee-for-service, DRG-based and capi-
tated payment arrangements.
The finding that one salvage technique—perfusion balloon
catheters—had an apparent negative associated incremental
cost warranted closer scrutiny. The catheters were almost
always used in association with other salvage techniques (23%
of patients had stenting, 46% had prolonged heparin use, 23%
had thrombolysis and only 31% had no other simultaneous
salvage technique), and most of the excess costs were allocated
to the other techniques.
Figure 2 summarizes the economic impact of one salvage
technique, stenting, as a function of its clinical effectiveness
and of the payer mix. Our model demonstrates that in a purely
fee-for-service environment, the less clinically effective strategy
is the most profitable. As DRG-based payers increase, this
situation is rapidly reversed. In a DRG-dominated environ-
ment, stenting cannot achieve cost savings for the hospital
regardless of its clinical effectiveness because the preventive
measure brings no added revenues, whereas the economic
impact of complications is driven by the fact that CABG is
amply rewarded. Therefore, in a DRG-based environment, it is
more profitable to have a mix of complications that includes
some CABGs than it is to prevent complications with salvage
techniques. The subsequent effects of an increase in capitated
payers are summarized in Figure 2. Salvage techniques become
cost-reducing because there are no independent revenues
associated with any event, including any of the complications.
CABG is no longer profitable; it is purely a source of greater
costs. Under a capitated system, the more clinically effective a
salvage technique, the more cost saving it is for the hospital.
The break-even point for clinical effectiveness for stenting to
become cost savings under a capitated system is 51%; that is, if
for approximately every two stents implanted, one complica-
tion is successfully prevented, the cost savings of prevented
complications will pay for the excess costs of the stenting.
Discussion
In the present study we have quantitated the costs, revenues
and contribution margin of several commonly used interven-
tional cardiology salvage strategies and the offsetting effects of
prevented complications as a framework for evaluating the
economic impact of salvage techniques. We have rendered
these analyses more generalizable by creating a model to
account for differences in payer mix and different degrees of
clinical effectiveness. Previous work in this field (9) raised
awareness of the high costs involved with interventional tech-
niques, but it did not account for the revenues, the concomi-
tant use of multiple modalities or the off-setting effects of
prevented complications. Whereas most previous discussions
of stents has focused on their higher costs than those of
conventional PTCA, we demonstrate that under certain con-
ditions, stenting can be cost saving for the hospital by prevent-
ing more costly complications. However, applying this concept
in clinical practice will prove challenging. As there are no
controlled clinical trials of stents as salvage tools (nor of any of
the other salvage modalities included in our study), we have
only a limited basis for assessing their effectiveness as salvage
tools. Two groups of investigators (16,25) have reported tem-
poral trends of CABG as a complication of PTCA since the
advent of stents. Altmann et al. (25) reported a decline in
emergency CABG that was almost exactly equal to the number
of stents implanted, a clinical effectiveness that approaches
100%. Lindsay et al. (16) reported a similar decline in emer-
gency CABG (;3%) but a stenting rate that approached 50%,
a figure that is closer to current practice at most centers. In
clinical practice, it is nearly impossible to precisely gauge the
clinical effectiveness of salvage techniques, but it is likely that
a practice of stenting in 50% of all PTCAs will not have a
sufficient offset of prevented complications to render stents
cost saving for the hospitals.
Table 2. Costs, Incremental Costs and Contribution Margins of Complications and Salvage Techniques
CABG MI
Repeat
PTCA
Prolonged
Heparin
Use Thrombolysis
Perfusion
Balloon Stenting
Total costs (per case) $25,972 $13,864 $15,389 $8,643 $10,988 $6,294 $13,316
Incremental costs $19,620 $6,289 $7,800 $1,055 $3,371 2$1,309 $5,736
Incremental contribution margin*
1995 UVM payer mix $3,765 2$2,094 $431 $178 $714 2$2,250 $856
Fee-for-service $9,665 $4,014 $4,055 $691 2$196 $372 $4,165
1996 DRG $5,459 2$6,003 2$4,875 2$996 2$4,969 2$804 2$6,545
Capitation system 2$19,620 2$6,289 2$7,800 2$1,055 2$3,371 $1,309 2$5,736
*The additional profit or loss to the hospital incurred by the complication or the salvage technique as compared with uncomplicated PTCA; a positive value indicates
additional profit to the hospital, and a negative value indicates a loss to the hospital. CABG 5 coronary artery bypass graft surgery; DRG 5 diagnosis-related group;
MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty; UVM 5 University of Vermont.
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Our results also illustrate how payment schemes can cause
clinical and financial incentives to become misaligned. Al-
though stenting is profitable for the hospital under fee-for-
service arrangements, under the DRG-based prospective pay-
ment system extant during the time of our study, clinically
effective behavior was economically detrimental. Whereas
complications (i.e., CABG) were financially rewarded, salvage
techniques were not. The physician is placed in the position
whereby acting in the best interests of the patient is directly
counter to the economic interests of the hospital, setting the
stage for potential conflicts of interest and contentious rela-
tions between hospital administration and physician staff. One
solution is to recalibrate the DRG system for stenting to reflect
both its ability to prevent complications and its long-term
benefits of reducing restenosis. In October 1996 the Health
Care Finance Administration recalibrated reimbursement for
DRG 112. However, because this higher reimbursement ap-
plied equally to conventional PTCA and to stenting, the
findings of our analyses are not altered by this recalibration.
Concern has been expressed (26) about the moral hazards
that capitation payment systems create. Because under these
systems providing less care can be financially rewarding, it is
feared that capitation could encourage physicians to withhold
care from patients inappropriately (26). However, in our
model, for the specific clinical question we probed, capitation
at least in part realigned financial and clinical incentives.
Under a capitated system, the hospital that successfully averts
CABG as a complication of PTCA when stents are implanted
realizes a financial benefit as the patient realizes a clinical
benefit. Furthermore, under a capitation system, the providers
also realize the long-term benefits of stenting in that fewer
repeat revascularizations are necessary (27), whereas under
current fee-for-service and DRG-based arrangements, the loss
of a subsequent revascularization represents a loss to the
hospital.
Limitations of the study. Our study has several limitations:
1. We examined the PTCA process after the point of entry
of the patient into the catheterization laboratory. That is, we
examined the economic effects of the interventional cardiolo-
gist’s behavior and decisions, but we did not examine the
economics of the decision of whether or not to undertake
percutaneous intervention. Furthermore, we limited our per-
spective to the initial episode of care. Although capitated
contracts and integrated health care delivery systems may
eventually erode the relevance of a single episode of care in
favor of a longer-term perspective, this is not the case at
present. Currently, capitation represents a small proportion of
total cardiovascular services, and the episode-of-care perspec-
tive remains the dominant payment method and will maintain
Figure 2. Economic impact of stenting
as a salvage tool under different evolv-
ing payer mixes. A, Economic impact of
stenting as a function of two variables:
1) clinical efficacy (i.e., how well stent-
ing may avert clinical complications),
and 2) the market share captured by
DRG-based payers. B, Economic im-
pact of stents similarly modeled as a
function of market share captured by
capitation system payers.
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its relevance for physicians and hospitals for the foreseeable
future.
2. We could not account for some indirect costs. If, for
example, emergency CABG forces postponement of a sched-
uled surgical case, the cost of the added length of stay of the
patient whose operation was canceled should be assigned to
the emergency case. However, we had no means of identifying
such indirect costs.
3. Our economic analyses are based on the unique cost
structure of our institution, and the cost structure of other
hospitals is likely to be different. However, our study provides
a framework that can be adapted to local practices and local
economic environments.
4. We did not evaluate every PTCA salvage modality
(10–13), restricting ourselves to techniques used with a mea-
surable frequency in our institution. Clinical practice will be
different in other localities. Interventional cardiology is evolv-
ing rapidly and new modalities are being incorporated into
clinical practice. For example, novel anticoagulant agents are
emerging as an important therapeutic option (28). However,
there are unavoidable temporal delays in gathering economic
data, in particular, revenue data.
5. Finally, we did not model either future changes in DRG
reimbursement for stenting (or other salvage techniques) or
future changes in stent costs. As new stents enter the market-
place, it is likely that stent prices will fall and new break-even
points will need to be calculated.
Conclusions. Our study has examined the economic impact
of PTCA salvage techniques on provider organizations by
considering multiple dimensions including costs, revenues, the
offsetting effects of prevented complications, and payer mix.
We have expanded economic analysis beyond the isolated
consideration of the single dimension of cost and have thus
developed a method that can be used to evaluate the costs and
savings associated with different interventional strategies and
techniques. Under fee-for-service arrangements, stenting is
profitable to the hospital at almost any level of clinical
effectiveness. Under current DRG systems, stenting will always
have a negative economic impact on the hospital, suggesting a
need to recalibrate the DRG system for stenting to realign
clinical and financial incentives. Under capitated systems,
stenting may be cost saving for the hospital at certain levels of
effectiveness in preventing complications, but in practice it is
nearly impossible to know the level of effectiveness being
achieved. Furthermore, at current levels of usage, stenting is
unlikely to pay for itself through prevented complications.
Appendix
Formulas Used in Iterative Analysis
Complications
K 5 No. of PTCAs without complications and with no salvage
strategy used: K 5 K1 1 K2 1 K3 1 K4 1 K5 1 K6, where 1 to
6 denote indications for PTCA (1 5 stable angina; 2 5 unstable
angina; 3 5 postmyocardial infarction; 4 5 primary therapy for
acute myocardial infarction; 5 5 cardiogenic shock; 6 5 other;
These subscripts are similarly applied to all subsequent catego-
ries below).
L 5 No. of PTCAs with subsequent CABG.
M 5 No. of PTCAs with subsequent myocardial infarction.
N 5 No. of PTCAs with subsequent out-of-laboratory acute vessel
closure and repeat PTCA.
Salvage Strategies
P 5 No. of PTCAs followed by prolonged heparin administration
alone.
Q 5 No. of PTCAs followed by use of perfusion balloon alone.
R 5 No. of PTCAs followed by use of thrombolytic agent alone.
S 5 No. of PTCAs followed by stenting alone.
T 5 No. of PTCAs followed by prolonged heparin administration 1
perfusion balloon.
U 5 No. of PTCAs followed by prolonged heparin administration 1
thrombolytic agents.
V 5 No. of PTCAs followed by prolonged heparin administration 1
thrombolytic agents 1 perfusion balloon.
W 5 No. of PTCAs followed by thrombolytic agents 1 perfusion
balloon.
X 5 No. of PTCAs followed with stenting 1 perfusion balloon.
Y 5 No. of PTCAs followed with stenting 1 thrombolytic agents.
Cost Calculations
ATCPTCA 5 Average total cost associated with PTCA without
complications and without salvage strategy; thus,
ATCPTCA21 5 Average total cost of PTCA for stable angina without
complications and without salvage strategy.
TCPi 5 Total costs of the ith case of PTCA followed by
strategy P (prolonged heparin administration) alone;
TCQi 5 Total cost of the ith case of PTCA followed with
strategy Q (perfusion balloon) alone; etc.
Incremental Costs of Salvage Strategies
Incremental costs (IC) of each salvage therapy are the average
costs of all cases involving salvage therapy less the incremental costs
attributable to any concomitant salvage therapy less the average cost of
an uncomplicated PTCA. Each IC calculation was carried out sepa-
rately for each of the clinical indications 1 to 6. A weighted average of
incremental cost for each salvage therapy was calculated on the basis
of relative frequency of PTCA for each indication. Thus,
Incremental costs of prolonged heparin 5 ICHeparin 5
FHSO
i
P
TCPiD1 SO
i
T
TCTiD1 SO
i
U
TCUiD1 SO
i
V
TCViD
2 ~T 1 V! p ICPerfusion balloon 2 ~U 1 V! p ICThrombolytic6
@~P 1 T 1 U 1 V!42 ATCPTCA.
Incremental costs for other salvage therapies were calculated in an
identical fashion.
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Incremental Costs of Complications
Incremental costs of bypass surgery 5 ICCABG 5 SO
i
L
ATCLiDY
L 2 (L1 p ATCPTCA21 1 L2 p ATCPTCA22 1 · · ·
1 L6pATCPTCA26)/(L1 1 L2 1 · · · 1 L6).
Equations for the incremental costs of myocardial infarction (MI)
and out of laboratory acute vessel closure with repeat PTCA paralleled
the equations for incremental costs of salvage therapy; that is, the
incremental cost of MI was the average total cost of all cases with MI
less the incremental cost of any concomitant complication (i.e., repeat
PTCA) less the average total cost of an uncomplicated PTCA.
Calculations for Contribution Margins
Contribution margins were calculated in the same manner as cost
calculations.
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